SIHUAN PHARM(00460) Key Financial Indicators

Quotes

Detailed Quotes

Company Overview

Company Profile Company Executives

Financial Analysis

Main Composition Key Indicators Financial Statement

Multi-dimentional Analyses

Company Valuation Capital Tracking Short Selling Data

YOY

Do not show

Hide blank lines

(FY)2021/12/31(Q6)2021/06/30(FY)2020/12/31(Q6)2020/06/30

Per Share IndicaTor

Operating Cash Flow Per Share

205.91% 0.0872 2396.33% 0.0782 -82.95% 0.0285 -97.9% 0.0031

Cash Flow Per Share

319.5% 0.1414 136.55% 0.0034 -130.3% -0.0644 -104.79% -0.0093

Operating Income Per Share

39.49% 0.4315 98.84% 0.2425 -9.15% 0.3093 -38.91% 0.122

Net Asset Per Share

-5.86% 1.086 25.48% 1.2515 1.82% 1.1536 -19.82% 0.9974

Basic Earning Per Share

-9% 0.0541 348.85% 0.0776 118.29% 0.0594 107.13% 0.0173

Diluted Earning Per Share

-9.62% 0.0537 346.07% 0.0772 118.29% 0.0594 107.13% 0.0173

Profitability

Gross Profit Ratio

-4.24% 74.394% 3.2% 76.925% -2.27% 77.690% -9.43% 74.540%

Operating Profit Ratio

-27.33% 23.211% 55.45% 46.453% 137.56% 31.942% 128.93% 29.884%

Net Profit Ratio

-65.95% 7.072% 127.76% 31.156% 121.75% 20.773% 111.58% 13.680%

Earning Before Tax Ratio

-52.48% 14.768% 49.98% 42.967% 136.37% 31.078% 127.58% 28.650%

ROE

-6.88% 4.840% 296.69% 6.460% 121.17% 5.197% 109.25% 1.629%

ROA

-19.5% 3.066% 288.69% 4.496% 119.64% 3.809% 108.39% 1.157%

Yield Quality

Operating Profit To Total Profits

52.92% 157.174% 3.65% 108.112% -- 102.779% -- 104.308%

Tax To Total Profits

82.19% 52.110% -37.76% 27.489% -- 28.601% -- 44.164%

Operating Cash To Total Revenue

119.31% 20.214% 1155.29% 32.251% -81.23% 9.217% -96.57% 2.569%

Capital Structure

Debt Assets Ratio

55.41% 36.877% -20.39% 25.347% 13.46% 23.729% 44.16% 31.838%

Equity Multipler

23.29% 1.7498 -4.45% 1.4534 8.46% 1.4193 14.52% 1.521

Debt Equity Ratio

87.78% 58.421% -27.31% 33.954% 17.64% 31.112% 64.78% 46.710%

Current Assets To tatal Assets

8.78% 53.405% -5.37% 50.099% -2.11% 49.097% 9.09% 52.940%

Non Current Assets To Total Assets

-8.46% 46.595% 6.04% 49.901% 2.12% 50.903% -8.57% 47.060%

Current Liabilities To tatal Liabilities

-40.71% 46.802% -20.88% 71.894% -8.2% 78.931% 2.06% 90.862%

Non Current Liabilities To Total Liabilities

152.5% 53.198% 207.57% 28.106% 50.34% 21.069% -16.73% 9.138%

Solvency

Current Ratio

18.04% 3.0943 50.23% 2.7492 -6.01% 2.6213 -25.85% 1.83

Quick Ratio

16.13% 2.8084 47.72% 2.5322 -7.26% 2.4184 -26.53% 1.7141

Operating Profit To Current Liabilities

-5.22% 0.3054 309.23% 0.3398 129.67% 0.3222 113.08% 0.083

Operrating Cash Flow To Current Liabilities

186.03% 0.2659 3204.52% 0.2359 -85.18% 0.093 -98.45% 0.0071

Share Equity Without Minority Interest To Total Liabilities

-47.81% 1.5497 31.45% 2.7144 -18.74% 2.9692 -39.43% 2.065

Operating Cash Flow To Total Liabilities

69.6% 0.1245 2514.89% 0.1696 -86.39% 0.0734 -98.42% 0.0065

Operating Profit To Total Liabilities

-43.8% 0.1429 223.8% 0.2443 127.24% 0.2543 113.35% 0.0755

Operating Capacity

Inventory Turnover（T）

12.79% 1.4081 33.09% 0.8335 -24.28% 1.2485 -28.92% 0.6263

Current Assets Turnover（T）

17.93% 0.4714 79.19% 0.2826 -15.36% 0.3998 -40.76% 0.1577

Fixed Assets Turnover（T）

19.68% 1.0497 64.53% 0.6188 -15.31% 0.8771 -37.06% 0.3761

Total Assets Turnover（T）

22.2% 0.2423 72.45% 0.1402 -2.48% 0.1983 -28.34% 0.0813

Growth Ability

Operating Revenue GR 3Y

292.35% 20.901% 268.16% 51.175% -14.31% -10.866% -285.7% -30.433%

Gross Income GR 3Y

339.4% 10.295% 268.52% 44.925% -191.63% -4.300% -161.54% -26.659%

Operating Profit GR 3Y

-10.98% -59.589% 92.83% -4.955% 75.03% -53.694% 77.07% -69.074%

EBT GR 3Y

-32.32% -74.113% 86.17% -9.849% 73.88% -56.009% 75.31% -71.213%

Net Profit GR 3Y

-29.75% -85.146% 72.02% -23.421% 75.13% -65.623% 77.12% -83.691%

Net Profit Attributable To The Parent Company GR 3Y

-7.25% -72.446% 77.03% -19.088% 74.11% -67.551% 77.34% -83.083%

Total Assets GR 3Y

106.96% 0.354% 82.58% -1.337% -261.31% -5.095% -416.01% -7.673%

Share Equity Without Minority Interest GR 3Y

-64.02% -29.202% 35.27% -14.760% -50% -17.803% -108.72% -22.801%

Equity GR 3Y

-77.25% -23.417% 52.03% -9.821% -40.99% -13.211% -141.29% -20.473%

Total Liabilities GR 3Y

219.77% 114.127% -10.74% 36.480% -69.27% 35.690% -46.79% 40.868%

Basic Earning Per Share GR 3Y

-7.04% -72.299% 77.14% -18.991% 75.26% -67.543% 78.8% -83.075%

Net Assets Per Share GR 3Y

-58.43% -28.131% 35.91% -14.586% -69.84% -17.756% -653.35% -22.757%

Other Indicators

Currency Unit

HKDHKDHKDHKD

Q6, Q9, and FY are cumulative quarterly reports: Q6 is the interim report; Q9 is third quarter report; FY is the annual report.

The MOM data from the Quarterly report，MOM=(current period - last period)/last period *100%

Company Overview More

Sihuan Pharmaceutical holding Group Co., Ltd. is a Hong Kong investment holding company engaged in pharmaceutical business. The company is mainly engaged in drug research and development, manufacturing and sales in China. Its products cover cardio-cerebrovascular, central nervous system, metabolism, tumor and anti-infection fields. Its products include cardiovascular and cerebrovascular products such as Klingo, Agili and Odime, as well as non-cardiovascular and cerebrovascular products such as Renao, metronidazole and roxatidine.

CEO： Fengsheng Che

Market： Hong Kong motherboard

Futu Hot List

HKUSCN

TradeSearchNews

SymbolLatest price%Chg

Watchlist